Intercept: Intercept loses Ocaliva FDA full approval bid in rare liver disease
Intercept's US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease treatment.
Read full article »
Intercept is a New Jersey-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of patients with non-viral liver diseases.
Read more